Literature DB >> 9699230

Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials.

P F Thall1, H G Sung.   

Abstract

We present some practical extensions and applications of a strategy proposed by Thall, Simon and Estey for designing and monitoring single-arm clinical trials with multiple outcomes. We show by application how the strategy may be applied to construct designs for phase IIA activity trials and phase II equivalence trials. We also show how it may be extended to incorporate the use of mixture priors in settings where a Dirichlet distribution does not adequately quantify prior experience, randomized phase II selection trials involving two or more experimental treatments, and trials with group-sequential monitoring for applications involving multiple institutions.

Mesh:

Substances:

Year:  1998        PMID: 9699230     DOI: 10.1002/(sici)1097-0258(19980730)17:14<1563::aid-sim873>3.0.co;2-l

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  22 in total

Review 1.  Stopping rules for phase II studies.

Authors:  N Stallard; J Whitehead; S Todd; A Whitehead
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

2.  A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.

Authors:  Mark A Schroeder; H Jean Khoury; Madan Jagasia; Haris Ali; Gary J Schiller; Karl Staser; Jaebok Choi; Leah Gehrs; Michael C Arbushites; Ying Yan; Peter Langmuir; Nithya Srinivas; Michael Pratta; Miguel-Angel Perales; Yi-Bin Chen; Gabrielle Meyers; John F DiPersio
Journal:  Blood Adv       Date:  2020-04-28

3.  Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.

Authors:  Fabio P S Santos; Hagop Kantarjian; David McConkey; Susan O'Brien; Stefan Faderl; Gautam Borthakur; Alessandra Ferrajoli; John Wright; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-08

4.  Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning.

Authors:  Christopher G Kanakry; Paul V O'Donnell; Terry Furlong; Marcos J de Lima; Wei Wei; Marta Medeot; Marco Mielcarek; Richard E Champlin; Richard J Jones; Peter F Thall; Borje S Andersson; Leo Luznik
Journal:  J Clin Oncol       Date:  2014-09-29       Impact factor: 44.544

5.  Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.

Authors:  Nathan H Fowler; R Eric Davis; Seema Rawal; Loretta Nastoupil; Fredrick B Hagemeister; Peter McLaughlin; Larry W Kwak; Jorge E Romaguera; Michelle A Fanale; Luis E Fayad; Jason R Westin; Jatin Shah; Robert Z Orlowski; Michael Wang; Francesco Turturro; Yasuhiro Oki; Linda C Claret; Lei Feng; Veerabhadran Baladandayuthapani; Tariq Muzzafar; Kenneth Y Tsai; Felipe Samaniego; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2014-10-15       Impact factor: 41.316

6.  Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.

Authors:  Lance C Pagliaro; Dallas L Williams; Danai Daliani; Michael B Williams; William Osai; Michael Kincaid; Sijin Wen; Peter F Thall; Curtis A Pettaway
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

7.  Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.

Authors:  Tapan M Kadia; Gautam Borthakur; Guillermo Garcia-Manero; Stefan Faderl; Elias Jabbour; Zeev Estrov; Sergerrne York; Xuelin Huang; Sherry Pierce; Mark Brandt; Charles Koller; Hagop M Kantarjian; Farhad Ravandi
Journal:  Br J Haematol       Date:  2012-02-24       Impact factor: 6.998

8.  Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.

Authors:  Yasuhiro Oki; Jason R Westin; Francisco Vega; Hubert Chuang; Nathan Fowler; Sattva Neelapu; Fredrick B Hagemeister; Peter McLaughlin; Larry W Kwak; Jorge E Romaguera; Michelle Fanale; Anas Younes; Maria Alma Rodriguez; Robert Z Orlowski; Michael Wang; Souzanne T Ouzounian; Felipe Samaniego; Luis Fayad
Journal:  Br J Haematol       Date:  2013-10-01       Impact factor: 6.998

9.  Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia.

Authors:  Alison Gardner; Gloria Mattiuzzi; Stefan Faderl; Gautam Borthakur; Guillermo Garcia-Manero; Sherry Pierce; Mark Brandt; Elihu Estey
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

10.  A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.

Authors:  Qaiser Bashir; Hassan Khan; Peter F Thall; Ping Liu; Nina Shah; Partow Kebriaei; Simrit Parmar; Betul Oran; Stefan Ciurea; Yago Nieto; Roy Jones; Chitra M Hosing; Uday R Popat; Yvonne T Dinh; Gabriela Rondon; Robert Z Orlowski; Jatin J Shah; Marcos De Lima; Elizabeth Shpall; Richard Champlin; Sergio Giralt; Muzaffar H Qazilbash
Journal:  Biol Blood Marrow Transplant       Date:  2013-07-17       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.